Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713366 | 0.91 | ADORA3 (0.39) | ADORA3ADORA2AADORA1POLBMAPT | |
| SCHEMBL6708820 | 0.90 | PARP14 (0.41) | NHERF1POLBPLCG2LMNA | |
| SCHEMBL6712023 | 0.89 | RAB9A (0.46) | CETPPOLBG6PDMAPTLMNA | |
| SCHEMBL6713713 | 0.89 | ADORA3 (0.37) | ADORA3ADORA2AADORA1POLBMAPT | |
| SCHEMBL6714114 | 0.88 | ALOX15 (0.45) | NHERF1PLCG2LMNA | |
| SCHEMBL6714268 | 0.88 | LMNA (0.39) | NHERF1POLBG6PDMAPTPLCG2 | |
| SCHEMBL6713400 | 0.88 | TP53 (0.35) | NHERF1POLBG6PDMAPTPLCG2 | |
| SCHEMBL6921109 | 0.87 | NPC1 (0.41) | POLBG6PDLMNA | |
| SCHEMBL6713077 | 0.87 | MEN1 (0.40) | ADORA3ADORA1NHERF1 | |
| SCHEMBL6712041 | 0.86 | LMNA (0.41) | ADORA1NHERF1POLBPLCG2CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | CETP 4517/4885ADORA3 3118/4885ADORA2A 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.